Sanofi S.A.

46-48 Avenue de la Grande Armée
Paris
France

Contact WebSite

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Article

04.06.2025 • News • Pharma

Sanofi to Acquire Blueprint Medicines

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology.

28.05.2025 • News • Pharma

Sanofi to Acquire Vigil Neuroscience

Sanofi to acquire Vigil Neuroscience, a clinical-stage biotech focused on therapies for neurodegenerative diseases.

20.02.2025 • News

Sanofi and CD&R Sign Share Purchase Agreement for Opella

Following completion of the required social and corporate procedures, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R).

04.12.2024 • News

Sanofi to Invest $1 Billion in New Insulin Manufacturing Site in China

Sanofi plans to invest around €1 billion ($1.1 billion) in the construction of a new insulin production facility in Beijing – the company's largest single investment in China to date. This was reported by Reuters and other news agencies.

21.10.2024 • News

Sanofi in Talks to Sell Stake in Opella to CD&R

Sanofi has entered into talks with Clayton Dubilier & Rice (CD&R), a US-based investment company, about the potential sale of a 50% controlling stake in the French drugmaker‘s consumer healthcare business, Opella.

14.05.2024 • News

Sanofi Invests €1 Billion to Boost Drug Manufacturing in France

On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.

23.01.2024 • News

Sanofi to Acquire Inhibrx for $1.7 Billion

Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also retain an 8% equity stake in New Inhibrx. Sanofi said that it expects to finance the transaction with available cash resources.

04.10.2023 • News

Sanofi Enters into Partnerships with Janssen and Teva

Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, a potential first-in-class product currently in Phase 3.

20.03.2023 • News

Sanofi in Lockstep with US Insulin Price Cuts

The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing sideward barbs at the system.

15.03.2023 • News

Sanofi Buying Diabetes Specialist Provention Bio

Paris-based French drugmaker Sanofi has agreed to acquire Provention Bio for $25 per share in cash, representing an equity value of about $2.9 billion. The publicly traded US biopharma focuses on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D).

19.01.2023 • News

Sanofi Strengthens Venture Capital Budget

As well as serving as a financial partner to fledgling companies, the VC fund supports future efforts for business development and M&A opportunities within its own operations, Sanofi said. The fresh capital injection will also fuel the expansion and investment capacity of its own investment team on a global scale.

15.11.2022 • News

Sanofi Enters Research Pact with Hong Kong’s Insilico

French pharma Sanofi has entered a multi-year, multi-target research collaboration worth up to $1.2 billion with Hong Kong biotech Insilico Medicine.

11.11.2022 • News

EU Approves Sanofi/GSK Covid Booster

After several delays and restarts and a lengthy review by the European Medicines Agency (EMA), the Covid-19 vaccine called VidPrevtyn Beta developed by the French-British partnership of Sanofi and GSK has been greenlighted by the European Commission.

05.07.2022 • News

Sanofi Joins Pfizer in nonprofit Drug Distribution

Two globally oriented drugmakers, Pfizer and Sanofi, are making moves that some may interpret as attempts to allay the pharma industry‘s reputation for being “only in it for the money” but could potentially benefit poorer countries if all goes to plan.

27.04.2022 • News

Sanofi Teams up with McLaren Racing

Sanofi has joined forces with McLaren Racing in a move it hopes will accelerate its manufacturing efficiency and performance drive. As the French drugmaker’s CEO Paul Hudson put it, “we want to run our lines with the speed, precision and efficiency of a Formula One racing team.”

31.03.2022 • News

Sanofi in Billion-Dollar Collaboration With IGM

French drugmaker Sanofi has signed an exclusive worldwide collaboration agreement with IGM Biosciences, a clinical-stage biotechnology company. The deal focuses on creating and developing and commercializing engineered IgM antibody antagonists against three oncology targets, along with three immunology/inflammation targets.

16.03.2022 • News

Sanofi and Blackstone in €300 Million Collaboration

Sanofi has agreed a €300 million collaboration with private equity investor Blackstone Life Sciences (BXLS) to advance its innovative treatment for multiple myeloma (MM) Sarclisa (isatuximab). The French drugmaker said it will continue to fully manage the clinical program and retain full rights and control of the treatment.